Chord Energy Corporation - Common Stock CHRD 深 沪
已收盘 10-03 16:00:00 美东时间
99.13
+1.610
+1.65%
华盛通- 最 高100.00
- 今 开97.89
- 成交量 75.69万股
- 最 低 97.89
- 昨 收 97.52
- 总市值 56.76亿
- 52周最高 131.039
- 市盈率 静 6.19
- 换手率 0.00%
- 52周最低 77.23
- 委 比 13.89%
- 总股本 5725.81万
- 历史最高 179.43
- 量 比 0.87
- 振 幅 2.16%
- 历史最低 -58.435
- 每 手 1
- 风险率 11.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Where Chord Energy Stands With Analysts
In the last three months, 15 analysts have published ratings on Chord Energy (N...
10-04 04:02
Piper Sandler Maintains Overweight on Chord Energy, Lowers Price Target to $167
Piper Sandler analyst Mark Lear maintains Chord Energy (NASDAQ:CHRD) with a Overweight and lowers the price target from $169 to $167.
10-03 23:08
Chord Energy Releases 2024 Sustainability Report
HOUSTON, Oct. 2, 2025 /PRNewswire/ -- Chord Energy Corporation (NASDAQ: CHRD) ("Chord" or the "Company") today announced the release of its 2024 Sustainability Report, which highlights Chord...
10-02 21:00
Chord Energy Completes $750M Senior Notes Offering
Chord Energy ( ($CHRD) ) has issued an update. On September 30, 2025, Chord Ene...
10-01 01:27
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
11 Analysts Have This To Say About Chord Energy
11 analysts have shared their evaluations of Chord Energy (NASDAQ:CHRD) during ...
09-17 05:01
Chord Energy plans $500M debt offering
Chord Energy (NASDAQ:CHRD) plans to offer $500 million in aggregate principal amount of senior unsecured notes due 2030 in a private placement to eligible purchasers. The company plans to use the net ...
09-16 19:42
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
